Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of DermBiont.

    Client Virtual Booth

    DERMBIONT

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    DermBiont
    United_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    451 D Street, Suite 908 Boston, MA 02210
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.dermbiont.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/dermbiont/
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    DermBiont Announces First Close of $35.2 Million in a Series B Financing to Advance First-in-Class Targeted Topical Dermatological Therapeutics

    Details:

    The net proceeds will be used to advance the clinical development of SM-020 for the treatment of seborrheic keratoses and SM-030 for the treatment of melasma and other hyperpigmentation disorders of the skin.


    Lead Product(s): SM-020

    Therapeutic Area: Dermatology Product Name: SM-020

    Highest Development Status: Phase IIProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Double Point Ventures

    Deal Size: $35.2 million Upfront Cash: Undisclosed

    Deal Type: Series B Financing October 24, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    DermBiont Announces Positive Data from a Phase 2 Trial Treating Solar Lentigos and Normalizing Pigmentation of the Skin with 0.8% SM-030 Topical Gel

    Details:

    SM-030 (ruboxistaurin) is a first-in-class selective and potent topical gel which is designed to inhibit PKCβ, which is the key and final enzyme in the melanin synthesis pathway, thus reduces the production of excess epidermal melanin.


    Lead Product(s): Ruboxistaurin

    Therapeutic Area: Dermatology Product Name: SM-030

    Highest Development Status: Phase IIProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable May 30, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    DermBiont Announces Positive Phase 2 Clinical Trial Data Treating Seborrheic Keratosis with SM-020, the First and Only Targeted Topical Treatment for th...

    Details:

    SM-020 is the first and only highly selective topical treatment that results in natural apoptosis of SK cells without cytotoxicity to healthy, normal keratinocytes.


    Lead Product(s): SM-020

    Therapeutic Area: Dermatology Product Name: SM-020

    Highest Development Status: Phase IIProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable June 23, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    DermBiont Raises $28 Million and Acquires Chromaderm to Expand Targeted Topical Therapeutics in Development

    Details:

    Acquisition of clinical-stage biotechnology company Chromaderm by DermBiont, will accelerate the development of Chromaderm’s drug candidate, ruboxistaurin (SM-030), topical formulation of the first and only targeted drug to treat skin hyperpigmentation.


    Lead Product(s): Ruboxistaurin

    Therapeutic Area: Dermatology Product Name: SM-030

    Highest Development Status: Phase IProduct Type: Small molecule

    Recipient: Chroma Dermatology

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Acquisition December 21, 2021

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-m-2024-04-29

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search